One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.

The firm will use the funding to support the Phase I trial of its CAR T-cell therapy, VIPER-101, in lymphoma patients.

Ideaya plans to submit an investigational new drug application next year for IDE034, a B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate.

NEW YORK – Canhelp Genomics on Monday said it is collaborating with Mirxes Singapore to provide solid tumor origin identification testing services in Singapore, Malaysia, Thailand, Indonesia, and the ...

Based on early Phase I/II trial data, Tango has decided to end enrollment in a study of TNG908 and focus resources on more promising drugs in its pipeline.

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

The funding will allow CUH to buy new equipment for administering treatments such as CAR T-cell therapies, reducing patients' need to travel long distances.

Relevant genes to test for hereditary prostate cancer include ATM, BRCA1, BRCA2, CHEK2, HOXB13, and TP53, according to the guidelines. For all four cancer types included in these guidelines, NCCN also ...

The drugmaker emphasized plans to move further away from singular reliance on Keytruda while reporting solid sales growth in ...

The restructuring is aimed at freeing up resources so the firm can advance its EBV-positive peripheral T-cell lymphoma drug toward the market.

NEW YORK — The denials UT Southwestern Medical Center's cancer center was receiving from one insurance company when it began billing for genetic counseling services didn't make sense: The genetic ...